Wobble Genomics’ Technology Demonstrates Potential in Accelerating Precision Medicine Innovations
Edinburgh, UK, 10th December 2024 – Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will this week present new data at the San Antonio Breast Cancer Symposium (SABCS) that demonstrates the ability of its technology platform to provide deep biological insights critical for drug discovery and development,1 building on previous data which established the technology’s strong predictive performance as a diagnostic tool.2
Within its prospective study, Wobble Genomics’ technology has uncovered hundreds of thousands of novel full-length RNA isoforms, many of which are cancer-specific and include previously uncharacterised variants of oncogenes and tumour suppressors.1 By enhancing the representation of important genes and transcripts that drive disease progression, Wobble’s technology shows promise as a tool for the discovery of new therapeutic targets, which could help enable the development of highly targeted cancer treatments such as mRNA cancer vaccines and antibody-drug conjugates (ADCs).1
Dr. Rick Hockett, leader in the field of immunology and personalised medicine and Chief Medical Officer at Wobble Genomics, said: “The recent findings reflect the transformative potential of Wobble Genomics’ technology. The additional biologic content in full length RNA holds great promise for cancer care and extend to a broad range of other applications including diagnostics, treatment monitoring, target discovery, and drug development, underscoring the versatility and impact of Wobble Genomics’ technology.”
The novel full-length RNA isoforms uncovered by Wobble’s technology have been captured within the company’s comprehensive database, containing therapeutically relevant targets for cancer treatments with over 35,000 cancer-specific RNA isoforms from its studies, which can enable the development of tailored treatments like RNA-based cancer vaccines and ADCs.1 These population-level targets are particularly significant because they represent shared tumour-specific properties across patients, making them ideal candidates for broadly applicable yet highly specific therapies. The unique protein-coding regions encoded by these isoforms can also serve as neoantigen targets for personalised immunotherapies, enabling RNA cancer vaccines or ADCs to precisely target cancer cells, while minimising harm to healthy tissue.
Dr. Richard Kuo, Founder and CEO of Wobble Genomics, said: “By bridging the gap between individual tumour profiles and population-level applicability, our database has the potential to provide a foundation for creating next-generation therapies that combine precision with scalability, ultimately advancing a novel approach in the fight against cancer with greater accuracy and efficiency. As we continue refining and expanding the capabilities of our technology, we’re poised to transform patient care, not just in cancer, but across a wide range of diseases by enhancing how we detect, monitor, and treat illness in ways that were previously unimaginable.”
Wobble Genomics’ platform has also demonstrated the ability to provide a comprehensive view of the patient’s immune system, which supports the potential development of immunotherapies tailored to specific immune profiles and enables patient stratification to optimise treatment responses.1 The identification of unique transcripts and novel cancer-specific targets further enhances the platform’s potential to advance precision oncology, by linking immune dynamics with tumour biology for highly targeted therapies.
